


Helping to bring heme/ onc therapies to cancer patients



Catalyst Oncology is a niche oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation hematologic oncology (heme/onc) therapies to cancer patients in need. Clinical trials in hematologic malignancies are complex, more so than in solid tumors and thus require a higher level of expertise in your CRO partner. Bringing effective heme/onc therapies to proof-of-concept and then to market as fast as possible is our mission because every second counts for patients and their families living with blood cancer.

Active portfolio in a range of heme/onc trials

- Leukemias
 - AML, CLL/SLL, CML
- Lymphomas
 - DLBCL, FL, MCL, NHL, PTCL
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Rare Indications
 - AITL, PTCL, MZL

We understand the nuances of heme/onc trials

- Complex endpoints
 - (Cheson, Lugano, IMWG etc.)
- Patients with significant comorbidities
- I/E criteria, wash-out windows, rescue medications
- Competitive clinical trial landscape
- Challenging enrollment rates



Exclusively Biotech-Focused

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye to rapid shifts when protocols amend or breakthrough designations move a product straight from Phase I to registration.





Seasoned Oncology Experts

With a minimum requirement of 5+ years of oncology experience for key roles, our oncology niche guarantees you a seasoned team across all functions.

A Transparent, 'People-First' Culture

We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites.

Additional Differentiators

			
Flexible solutions and best-in-class technologies	Data-centric approach with visual analytics and clinical science	Catalyst Oncology Site Network	Global Footprint: 1000+ across US, EU & APAC

Active Next-Gen Oncology Experience

Working largely in early- to mid-phase development across a range of both solid and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.

